Ok, that is a lot of money. I won't look into how much of that went in his pocket, but surely enough to make him rich. It's still a drop in the bucket compared to his Samumed valuation, and being rich never stopped people from trying to become more rich by any means possible. There's no way that SM modulates the Wnt pathway in as potent a fashion as Surrozen's drugs, yet Surrozen isn't a billion dollar company, at least not yet. You also don't see Surrozen running around hyping up their drugs to everyone who will listen, calling them cures. They have more basis for doing that than Samumed, yet they aren't. Kibar is the snake oil salesman getting all the attention and money hawking cures for all your ailments in town square while Surrozen is working away quietly and studiously on advancing medicine. When they release their revolutionary treatments the treatments will speak for themselves. They won't need the flash and hyperbole that Kibar is famous for.Wrong, he was (very) rich before Samumed
In the late 1990s, when he was finishing his doctorate, he invented a cancer diagnosis system, which he turned into a company called Genoptix. The company went public a few years later, and was purchased by Novartis in 2011 for $476 million.
After completing his education, Kibar moved to New York City, where he worked for the hedge fund sponsor Pequot Capital.
Osman Kibar
en.wikipedia.org